Wiley Matthew T. has filed 17 insider transactions across 2 companies since March 2023.
Most recent transaction: a grant/award of 115000 shares of Definium Therapeutics, Inc. ($DFTX) on February 03, 2026.
Activity breakdown: 0 open-market purchases and 4 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 3, 2026 | Definium Therapeutics, Inc. | $DFTX | Wiley Matthew T. | Chief Commercial Officer | A | Common Shares | 115000 | $0.00 | 115,000.0000 | 98,509,279 | 9999.99% | 0.12% |
| July 22, 2024 | BioXcel Therapeutics, Inc. | $BTAI | Wiley Matthew T. | Other | A | Stock Option (right to buy) | 1875 | $0.00 | 1,875.0000 | 2,516,000 | 9999.99% | 0.07% |
| March 17, 2025 | Definium Therapeutics, Inc. | $DFTX | Wiley Matthew T. | Chief Commercial Officer | A | Stock Option (Right to Buy) | 350000 | $0.00 | 350,000.0000 | 75,368,359 | 9999.99% | 0.46% |
| Oct. 3, 2024 | BioXcel Therapeutics, Inc. | $BTAI | Wiley Matthew T. | Chief Commercial Officer | S | Common Stock | 6272 | $0.55 | 19,011.0000 | 2,649,000 | 24.81% | 0.24% |
| Sept. 17, 2024 | BioXcel Therapeutics, Inc. | $BTAI | Wiley Matthew T. | Chief Commercial Officer | A | Common Stock | 21250 | $0.00 | 25,283.0000 | 2,516,000 | 526.90% | 0.84% |
| Sept. 15, 2024 | BioXcel Therapeutics, Inc. | $BTAI | Wiley Matthew T. | Chief Commercial Officer | M | Common Stock | 750 | $0.00 | 4,248.0000 | 2,516,000 | 21.44% | 0.03% |
| Sept. 16, 2024 | BioXcel Therapeutics, Inc. | $BTAI | Wiley Matthew T. | Chief Commercial Officer | S | Common Stock | 215 | $0.69 | 4,033.0000 | 2,516,000 | 5.06% | 0.01% |
| Sept. 15, 2024 | BioXcel Therapeutics, Inc. | $BTAI | Wiley Matthew T. | Chief Commercial Officer | M | Restricted Stock Units | 750 | $0.00 | 7,500.0000 | 2,516,000 | 9.09% | 0.03% |
| June 15, 2024 | BioXcel Therapeutics, Inc. | $BTAI | Wiley Matthew T. | Chief Commercial Officer | M | Restricted Stock Units | 750 | $0.00 | 8,250.0000 | 1,929,000 | 8.33% | 0.04% |
| June 15, 2024 | BioXcel Therapeutics, Inc. | $BTAI | Wiley Matthew T. | Chief Commercial Officer | M | Restricted Stock Units | 750 | $0.00 | 8,250.0000 | 1,929,000 | 10.00% | 0.04% |
| June 15, 2024 | BioXcel Therapeutics, Inc. | $BTAI | Wiley Matthew T. | Chief Commercial Officer | M | Common Stock | 750 | $0.00 | 3,742.0000 | 1,929,000 | 25.07% | 0.04% |
| June 17, 2024 | BioXcel Therapeutics, Inc. | $BTAI | Wiley Matthew T. | Chief Commercial Officer | S | Common Stock | 244 | $1.26 | 3,498.0000 | 1,929,000 | 6.52% | 0.01% |
| March 15, 2024 | BioXcel Therapeutics, Inc. | $BTAI | Wiley Matthew T. | CHIEF COMMERCIAL OFFICER | M | Restricted Stock Units | 3000 | $0.00 | 9,000.0000 | 1,821,000 | 50.00% | 0.16% |
| April 4, 2024 | BioXcel Therapeutics, Inc. | $BTAI | Wiley Matthew T. | CHIEF COMMERCIAL OFFICER | S | Common Stock | 1008 | $2.64 | 2,992.0000 | 1,929,000 | 25.20% | 0.05% |
| March 15, 2024 | BioXcel Therapeutics, Inc. | $BTAI | Wiley Matthew T. | CHIEF COMMERCIAL OFFICER | M | Common Stock | 3000 | $0.00 | 3,000.0000 | 1,821,000 | 9999.99% | 0.16% |
| March 15, 2023 | BioXcel Therapeutics, Inc. | $BTAI | Wiley Matthew T. | CHIEF COMMERCIAL OFFICER | A | Restricted Stock Units | 12000 | $0.00 | 12,000.0000 | 28,015,000 | 9999.99% | 0.04% |
| March 15, 2023 | BioXcel Therapeutics, Inc. | $BTAI | Wiley Matthew T. | CHIEF COMMERCIAL OFFICER | A | Stock Option (Right to Buy) | 36000 | $0.00 | 36,000.0000 | 28,015,000 | 9999.99% | 0.13% |